SpringWorks Therapeutics, Inc. (SWTX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
SpringWorks Therapeutics, Inc. (SWTX) Bundle
Explore the financial future of SpringWorks Therapeutics, Inc. (SWTX) with our user-friendly DCF Calculator! Enter your assumptions regarding growth, margins, and costs to uncover the intrinsic value of SpringWorks Therapeutics, Inc. (SWTX) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 35.0 | .0 | 6.1 | 5.4 | 3.9 | 2.8 | 2.0 | 1.5 | 1.1 |
| Revenue Growth, % | 0 | 0 | -100 | 0 | -11.39 | -27.85 | -27.85 | -27.85 | -27.85 | -27.85 |
| EBITDA | -59.0 | -46.0 | -173.0 | -280.7 | -341.3 | -.8 | -.6 | -.4 | -.3 | -.2 |
| EBITDA, % | 100 | -131.36 | 100 | -4566.03 | -6266.68 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | .2 | .3 | .5 | 1.9 | 1.7 | 2.1 | 1.5 | 1.1 | .8 | .6 |
| Depreciation, % | 100 | 0.99714 | 100 | 30.84 | 30.6 | 52.49 | 52.49 | 52.49 | 52.49 | 52.49 |
| EBIT | -59.2 | -46.3 | -173.5 | -282.6 | -343.0 | -.8 | -.6 | -.4 | -.3 | -.2 |
| EBIT, % | 100 | -132.35 | 100 | -4596.88 | -6297.28 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 327.7 | 508.5 | 373.5 | 597.0 | 479.2 | 3.9 | 2.8 | 2.0 | 1.5 | 1.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | 5.9 | 2.4 | 1.7 | 1.2 | .9 | .6 |
| Account Receivables, % | 100 | 0 | 100 | 0 | 108.87 | 60 | 60 | 60 | 60 | 60 |
| Inventories | .0 | .0 | .0 | .0 | 3.1 | 2.0 | 1.5 | 1.1 | .8 | .5 |
| Inventories, % | 100 | 0 | 100 | 0 | 56.97 | 51.39 | 51.39 | 51.39 | 51.39 | 51.39 |
| Accounts Payable | 2.7 | 1.4 | 3.4 | 8.0 | 7.4 | 3.2 | 2.3 | 1.7 | 1.2 | .9 |
| Accounts Payable, % | 100 | 3.86 | 100 | 130.31 | 135.78 | 80.77 | 80.77 | 80.77 | 80.77 | 80.77 |
| Capital Expenditure | -.7 | -.6 | -2.0 | -10.2 | -7.4 | -1.6 | -1.1 | -.8 | -.6 | -.4 |
| Capital Expenditure, % | 100 | -1.83 | 100 | -165.87 | -135.58 | -40.37 | -40.37 | -40.37 | -40.37 | -40.37 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -55.6 | -45.0 | -172.8 | -279.3 | -343.0 | -.8 | -.6 | -.4 | -.3 | -.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -53.5 | -46.6 | -172.2 | -283.0 | -358.4 | .1 | .1 | .1 | .1 | .0 |
| WACC, % | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 | 8.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | .4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 1 | |||||||||
| Present Terminal Value | 1 | |||||||||
| Enterprise Value | 1 | |||||||||
| Net Debt | -169 | |||||||||
| Equity Value | 170 | |||||||||
| Diluted Shares Outstanding, MM | 63 | |||||||||
| Equity Value Per Share | 2.69 |
What You Will Get
- Real SpringWorks Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for SpringWorks Therapeutics, Inc. (SWTX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to suit your analysis needs.
- Instant Valuation Updates: Automatic recalculations to assess the impact of changes on SpringWorks' fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
- Time-Saving and Accurate: Eliminate the hassle of building models from scratch while ensuring precision and adaptability.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for SpringWorks Therapeutics, Inc. (SWTX).
- WACC Calculator: Pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth rates, research and development expenditures, and discount rates as needed.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to SpringWorks Therapeutics, Inc. (SWTX).
- Interactive Dashboard and Charts: Visual representations that summarize key valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered SpringWorks Therapeutics data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for SpringWorks Therapeutics' intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose SpringWorks Therapeutics, Inc. (SWTX)?
- Innovative Solutions: Access cutting-edge therapies designed to tackle unmet medical needs.
- Commitment to Quality: Rigorous research and development processes ensure high standards.
- Patient-Centric Approach: Focused on improving patient outcomes through tailored treatments.
- Expert Team: Collaborate with industry leaders and experienced professionals in the field.
- Proven Track Record: Backed by successful clinical trials and positive patient feedback.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about buying or selling SpringWorks Therapeutics stock (SWTX).
- Financial Analysts: Enhance valuation processes with comprehensive financial models tailored for SpringWorks Therapeutics.
- Consultants: Provide clients with accurate and timely valuation insights for SpringWorks Therapeutics.
- Business Owners: Learn how biotech companies like SpringWorks Therapeutics are valued to inform your own business strategies.
- Finance Students: Explore valuation methodologies using real-world data and case studies from SpringWorks Therapeutics.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled SpringWorks Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for SpringWorks Therapeutics (SWTX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.